Our Laboratories

Endocrinology, Metabolism and Diabetes

About us

As an expert group of endocrinology, metabolism, and diabetes, we provide the best medical care for patients with endocrine disorders, diabetes, and obesity.
Kyushu University is one of highest volume centers for endocrine disorders in Japan. We have basic and clinical experiences and clinical database on well-known adrenal diseases (adrenal incidentaloma, primary aldosteronism, Cushing’s syndrome, pheochromocytoma) as well as rare adrenal diseases such as congenital adrenal hyperplasia and adrenal cortical carcinoma. Recently, we have launched a unique outpatient clinic on pituitary diseases, where patients with pituitary dysfunction are treated medically and/or surgically, in cooperation with expert physicians in Department Neurosurgery.
Our group has made commitment to diabetes care for type1 diabetes, type2 diabetes, gestational diabetes, secondary diabetes. Diabetic patients are evaluated and thus medically treated on a personalized basis, with standard methods plus state-of-the-art technologies such as CGM (continuous glucose monitoring), FGM (flash glucose monitoring), and insulin pump. They are examined for early detection of diabetic complications and prevention of their progression. Our expert diabetes team consists of expert physicians, certified diabetes educators, pharmacists, dieticians, qualified nurses, and other medical staffs. To pursue a high standard of comprehensive diabetes care, we work collaboratively with research investigators engaged in clinical trials. We are also actively engaged in obesity treatment. In addition to standard diet and exercise therapies, we conduct pharmacotherapy based on endocrine metabolic approaches, bariatric surgery, and behavioral therapy, in cooperation with expert physicians and medical staffs.
Our research aims to identify mechanisms underlying the pathogenesis of endocrine and metabolic disorders. Studies are in progress to identify the pathophysiologic roles of inter-organ network that comprises the adipose tissue, liver, skeletal muscle, and intestine, in the pathophysiology of diabetes, obesity, and their complications such as NASH, sarcopenia, and so forth. In addition, a number of protocols are underway exploring new diagnostics and therapeutics for endocrine and metabolic diseases as well as means of primary prevention for these diseases.

Selected publications

  • H. Umakoshi, R. Sakamoto, Y. Matsuda, M. Yokomoto-Umakoshi, H. Nagata, T. Fukumoto, M. Ogata, Y. Ogawa. Q-AND-A study group. Role of Aldosterone and Potassium Levels in Sparing Confirmatory Tests in Primary Aldosteronism. J Clin Endocrinol Metab. 2019. [Epub ahead of print]
  • R. Takei, T. Inoue, N. Sonoda, M. Kohjima, M. Okamoto, R. Sakamoto, T. Inoguchi, Y. Ogawa. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS One. 14: e0223302, 2019.
  • Y. Kodama, F. Hyodo, M. Yamato, K. Yasukawa, Y. Minami, N. Sonoda, Y. Ogawa, K. Ichikawa, T. Inoguchi. Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice. Kidney Int. 96:787-792, 2019.
  • T. Maki, S. Maeno, Y. Maeda, M. Yamato, N. Sonoda, Y. Ogawa. M. Wakisaka, T. Inoguchi. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells. Sci. Rep. 9:4703, 2019.
  • S. Yano, K. Ashida, H. Nagata, K. Ohe, N. Wada, Y. Takeichi, Y. Hanada, Y. Ibayashi, L. Wang, S. Sakamoto, R. Sakamoto, H. Uchi, M. Siratsuchi, M. Furue, M. Nomura, Y. Ogawa. Nivolumab-induced thyroid dysfunction lacking antithyroid is frequently evoked in Japanese patients with malignant melanoma. BMC Endocr Disord. 18:36, 2018.
  • Y. Minami, N. Sonoda, E. Hayashida, H. Makimura, M. Ide, N. Ikeda, M. Ohgidani, TA. Kato, Y. Seki, Y. Maeda, S. Kanba, R. Takayanagi, Y. Ogawa, T. Inoguchi. P66Shc Signaling Mediates Diabetes-Related Cognitive Decline. Sci. Rep. 8:3213, 2018.